13F reference period
Q2 2026
Security Snapshot
Tonix Pharmaceuticals Holding Corp. - Common Stock, par value $0.001 per share (TNXP) Institutional Ownership
CUSIP: 890260839
13F Institutional Holders and Ownership History from Q4 2024 to Q3 2026
Institutions Reporting
101
Shares (Excl. Options)
9.36M
Full value: 9,356,425 · shares · 30 Jun 2026Price
$12.76
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- TNXP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 9,356,425
- Total 13F value
- $119,407,304
- Portfolio coverage rank
- 0%
- Share change
- +4,495,122
- Value change
- +$57,341,129
- Number of holders
- 101
- Shares outstanding
- 16,628,592
- SEC-reported price per share
- $6.13
- Insider filing price
- $6.13
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- TNXP - Tonix Pharmaceuticals Holding Corp. - Common Stock, par value $0.001 per share is tracked under CUSIP 890260839.
- 101 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 81 to 101 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$66.97M
Full value: $66,966,212 · USD · 31 Mar 2026.$119.41M
Full value: $119,407,304 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 101 institutions filings for Q2 2026.
Security key
890260839
13F reference period
Q2 2026
13F holders
101
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
TNXP full holder history
Tonix Pharmaceuticals Holding Corp. SEC filings
Tonix Pharmaceuticals Holding Corp. company facts
Tonix Pharmaceuticals Holding Corp. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 890260839:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
TNXP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 9.2% | $19,884,434 | 1,235,058 | Point72 Asset Management, L.P. | 29 Dec 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 5.6% | $12,322,665 | 890,366 | Millennium Management LLC | 09 Jun 2026 | |||
| AQR CAPITAL MANAGEMENT LLC | 5.5% | $11,217,782 | 882,595 | AQR Capital Management, LLC | 30 Jun 2026 | |||
| BlackRock, Inc. | 6.7% | -14% | $13,348,524 | +$2,726,362 | 854,579 | +26% | BlackRock, Inc. | 31 Dec 2025 |
| Sirenia Capital Management LP | 4.9% | $10,356,121 | 814,801 | Sirenia Capital Management LP | 30 Jun 2026 | |||
| VANGUARD GROUP INC | 5% | -22% | $10,521,710 | +$1,822,042 | 673,605 | +21% | The Vanguard Group | 31 Dec 2025 |
As of 30 Jun 2026,
101
institutional investors reported holding
shares of
Tonix Pharmaceuticals Holding Corp. - Common Stock, par value $0.001 per share (TNXP).
This represents
56%
of the company’s total
outstanding shares.
9.36M
Full value: 9,356,425 · shares · 30 Jun 202616.63M
Full value: 16,628,592 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
51%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.4% | 1,398,041 | +44% | 0% | $17,839,002 |
| Point72 Asset Management, L.P. | 7% | 1,166,752 | +830% | 0.02% | $14,887,756 |
| MILLENNIUM MANAGEMENT LLC | 5.8% | 966,932 | +340% | 0.01% | $12,338,052 |
| AQR CAPITAL MANAGEMENT LLC | 5.3% | 882,595 | +447% | 0% | $11,261,911 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 691,895 | +33% | 0% | $8,828,580 |
| Jones Hill Capital LP | 3.8% | 625,428 | +38% | 1.7% | $7,980,461 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 395,260 | +26% | 0% | $5,044,670 |
| Ishara Investments LP | 2% | 338,250 | 3.3% | $4,316,070 | |
| STATE STREET CORP | 1.6% | 271,374 | +18% | 0% | $3,462,732 |
| UBS Group AG | 1.4% | 231,682 | +0% | 0% | $2,956,262 |
| CITADEL ADVISORS LLC | 1.2% | 195,859 | -58% | 0% | $2,499,161 |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 0.99% | 165,144 | 0.28% | $2,107,237 | |
| Balyasny Asset Management L.P. | 0.8% | 132,591 | -58% | 0% | $1,691,861 |
| NORTHERN TRUST CORP | 0.72% | 120,386 | +20% | 0% | $1,536,126 |
| Nuveen, LLC | 0.71% | 117,447 | +24% | 0% | $1,498,624 |
| VANGUARD FIDUCIARY TRUST CO | 0.61% | 102,054 | +21% | 0% | $1,302,209 |
| GOLDMAN SACHS GROUP INC | 0.59% | 98,356 | +85% | 0% | $1,255,023 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.59% | 97,954 | +25% | 0% | $1,249,893 |
| FMR LLC | 0.56% | 93,551 | +5283% | 0% | $1,193,714 |
| IEQ CAPITAL, LLC | 0.56% | 92,373 | +543% | 0.01% | $1,178,679 |
| Susquehanna Portfolio Strategies, LLC | 0.39% | 65,024 | 0.01% | $829,706 | |
| SUPERSTRING CAPITAL MANAGEMENT LP | 0.38% | 63,648 | +0.17% | 0.51% | $812,148 |
| Trexquant Investment LP | 0.38% | 63,635 | 0.01% | $811,983 | |
| BANK OF AMERICA CORP /DE/ | 0.37% | 60,977 | +0.03% | 0% | $778,067 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.35% | 57,943 | 0% | $739,353 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Headline period
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 798,960 | $7,749,575 | +$1,398,329 | $9.74 | 25 |
| 2026 Q2 | 9,356,425 | $119,407,304 | +$57,341,129 | $12.76 | 101 |
| 2026 Q1 | 4,869,103 | $66,966,212 | +$8,767,315 | $13.75 | 81 |
| 2025 Q4 | 3,742,749 | $58,486,083 | +$19,805,765 | $15.62 | 70 |
| 2025 Q3 | 2,357,754 | $56,965,413 | +$23,004,291 | $24.16 | 60 |
| 2025 Q2 | 1,387,298 | $49,914,163 | +$34,081,287 | $35.98 | 46 |
| 2025 Q1 | 473,835 | $8,469,550 | +$8,375,403 | $17.88 | 24 |
| 2024 Q4 | 5,377 | $1,773 | +$1,773 | $0.33 | 2 |